Analysts Maintain Optimism Despite Harmony Biosciences Stock Dip Harmony Biosciences stock recently touched a 52-week low, trading near $28.90, yet analysts remain bullish with consensus price targets above $50. Strong financials, including 23% annual revenue growth and a robust drug pipeline, underpin this optimism, even as short-term volatility and industry headwinds persist.123